Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Digestion and Medical Imageology(Electronic Edition) ›› 2023, Vol. 13 ›› Issue (01): 26-32. doi: 10.3877/cma.j.issn.2095-2015.2023.01.006

• Evidence-Based Medicine • Previous Articles     Next Articles

Meta analysis of somatostatin combined with ulinastatin in the treatment of gastrointestinal bleeding

Langhuan Zhou1,(), Weiling Gong2, Fuchun Sun1, Song Song1   

  1. 1. Department of Clinical Pharmacy, Chengyang People′s Hospital of Qingdao, Qingdao 266109, China
    2. Department of Drug Safety Supervision, Pharmaceutical Instrument Supervision and Inspection Station, Joint Logistic Support Force, Beijing 100071, China
  • Received:2022-09-20 Online:2023-02-01 Published:2023-03-10
  • Contact: Langhuan Zhou

Abstract:

Objective

To systematically evaluate the efficacy and safety of somatostatin combined with ulinastatin in the treatment of gastrointestinal hemorrhage.

Methods

CNKI, VIP, Wanfang, CBM database, PubMed, Cochrane Library, EMBase were searched to collect randomized controlled trials of somatostatin combined with ulinastatin in the treatment of gastrointestinal bleeding.Mete analysis was performed using Revman 5.3 software.

Results

A total of 16 studies involving 1466 patients were included.The results showed that somatostatin combined with ulinastatin was better than somatostatin alone in the total effective rate(RR=1.24, 95% CI: 1.19-1.31, P<0.000 01), interleukin-2(SMD=1.10, 95% CI: 0.38-1.81, P=0.003), interleukin-6(SMD=-3.40, 95% CI: -4.69--2.12, P<0.000 01), interleukin-10(SMD=2.77, 95% CI: 1.66-3.87, P<0.000 01), tumor necrosis factor-α(SMD=-2.56, 95% CI: -3.26--1.87, P<0.000 01), hospitalization time(SMD=-1.75, 95% CI: -2.24--1.26, P<0.000 01)and gastrointestinal hemostasis time(SMD=-3.55, 95% CI: -4.11--2.99, P<0.000 01). There was no statistically significant difference in the incidence of adverse reactions between the two groups(SMD=0.79, 95% CI: 0.47-1.32, P=0.38), and both were lower.

Conclusion

Somatostatin combined with ulinastatin in the treatment of gastrointestinal bleeding is safe and effective, but it needs more high-quality clinical trials to verify.

Key words: Gastrointestinal bleeding, Ulinastatin, Somatostatin, Meta analysis

京ICP 备07035254号-15
Copyright © Chinese Journal of Digestion and Medical Imageology(Electronic Edition), All Rights Reserved.
Tel: 0531-83086377 15564155687 E-mail: zhxhbyyxzz@126.com
Powered by Beijing Magtech Co. Ltd